

Serial No.: 09/787,334

Docket No. 2861-4003

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claim 1 (currently amended) ~~An antagonist of A~~ prostaglandin F2 receptor antagonist comprising consisting essentially of an amino acid sequence selected from the group consisting of ILGHRDYK (PCP-8; SEQ ID NO:1); ILAHRDYK (PCP-13.7; SEQ ID NO:4); ILGFRDYK (PCP-13.11; SEQ ID NO:5); ILGHKDYK (PCP-13.13; SEQ ID NO:6); ILGHRNYK (PCP-13.14; SEQ ID NO:7); ILGHQDYK (PCP-13.18; SEQ ID NO:8); ILGHRDY-amide (PCP-13.20; SEQ ID NO:9); ILGHRDYK-amide (PCP-13.21; SEQ ID NO:1); ILGWRDYK (PCP-13.22; SEQ ID NO:10); and ILGXRDYK (PCP-13.24; SEQ ID NO:11), wherein X is cyclohexyl alanine.

Claim 2 (currently amended) A peptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 1 and 4 to 11 and wherein said amino acid sequence contains L- and/or D-amino acids, ~~an~~ and the amino acid sequence has ~~at least~~ about ~~75~~88 % homology to SEQ ID NOs: 1 and 4 to 11, wherein said peptide is a prostaglandin F2 receptor antagonist.

Claim 3 (currently amended) A method for ~~preventing~~ reducing the occurrence of premature delivery of fetus, which comprises the step of administering to a female in need of such treatment a therapeutically effective amount of the antagonist of claim 1.

Claim 4 (currently amended) A method for ~~preventing~~ reducing the occurrence of and/or treating dysmenorrhea comprising the step of administering to a female in need of such treatment a therapeutically effective amount of the antagonist of claim 1.

Claim 5 (previously amended) A pharmaceutical composition containing at least one antagonist of claim 1, mixture thereof, in association with a pharmaceutically acceptable carrier.

Claim 6 (withdrawn).

Serial No.: 09/787,334

Docket No. 2861-4003

Claim 7 (withdrawn).

Claim 8 (cancelled).

Claim 9 (cancelled).

C'  
Claim 10 (previously added) A method for reducing uterine contraction comprising the step of administering to a female in need of such treatment a therapeutically effective amount of the antagonist of claim 1.

---